PT  - JOURNAL ARTICLE
AU  - Lei-Yun Wang
AU  - Jia-Jia Cui
AU  - Qian-Ying OuYang
AU  - Yan Zhan
AU  - Yi-Min Wang
AU  - Xiang-Yang Xu
AU  - Cheng-Xian Guo
AU  - Ji-Ye Yin
TI  - Genetic Profiles in Pharmacogenes Indicate Personalized Drug Therapy for COVID-19
AID  - 10.1101/2020.03.23.20041350
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.03.23.20041350
4099  - http://medrxiv.org/content/early/2020/03/30/2020.03.23.20041350.short
4100  - http://medrxiv.org/content/early/2020/03/30/2020.03.23.20041350.full
AB  - Background The coronavirus disease 2019 (COVID-19) has become a global pandemic currently. Many drugs showed potential for COVID-19 therapy. However, genetic factors which can lead to different drug efficiency and toxicity among populations are still undisclosed in COVID-19 therapy.Methods We selected 67 potential drugs for COVID-19 therapy (DCTs) from clinical guideline and clinical trials databases. 313 pharmaco-genes related to these therapeutic drugs were included. Variation information in 125,748 exomes were collected for racial differences analyses. The expression level of pharmaco-genes in single cell resolution was evaluated from single-cell RNA sequencing (scRNA-seq) data of 17 healthy adults.Results Pharmacogenes, including CYP3A4, ABCB1, SLCO1B1, ALB, CYP3A5, were involved in the process of more than multi DCTs. 224 potential drug-drug interactions (DDIs) of DCTs were predicted, while 112 of them have been reported. Racial discrepancy of common nonsynonymous mutations was found in pharmacogenes including: VDR, ITPA, G6PD, CYP3A4 and ABCB1 which related to DCTs including ribavirin, α-interferon, chloroquine and lopinavir. Moreover, ACE2, the target of 2019-nCoV, was only found in parts of lung cells, which makes drugs like chloroquine that prevent virus binding to ACE2 more specific than other targeted drugs such as camostat mesylate.Conclusions At least 17 drugs for COVID-19 therapy with predictable pharmacogenes should be carefully utilized in risk races which are consisted of more risk allele carriers. At least 29 drugs with potential of DDIs are reported to be affected by other DDIs, they should be replaced by similar drugs without interaction if it is possible. Drugs which specifically targeted to infected cells with ACE2 such as chloroquine are preferred in COVID-19 therapy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNational Natural Science Foundation of China (81773823, 81573463, 81974511) National Science and Technology Major Project of China (2017ZX09304014, 2019ZX09201-002-006).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are presented in supplementary data.ARDSacute respiratory distress syndromeABCB1ATP binding cassette subfamily B member 1ACEangiotensin I converting enzymeACEIACE inhibitorsCOVID-19coronavirus disease 2019CYPcytochrome P450 familyCPICClinical Pharmacogenetics Implementation ConsortiumDCTsdrugs for COVID-19 therapyDDIsdrug-drug interactionsG6PDglucose-6-phosphate dehydrogenase.ITPAinosine triphosphataseNDEnarrow distribution enzymesPGxpharmacogeneticsSNPsingle nucleotide polymorphismSLCsolute carrier familySLCOSLC organic anion transporter familySc-RNA seqsingle cell RNA-sequencingTMPRSS2transmembrane serine protease 2VDRvitamin D receptorWDEwide distribution enzymes2019-nCoV2019 novel coronavirus